EyePoint Pharmaceuticals, Inc.

EYPT

US30233G2093

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
16.16 ^USD	-1.88%		-7.66%	-30.07%

Apr. 02	EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	CI
Mar. 18	EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	CI

Eyepoint Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 04, 2021 at 07:05 am EDT

EyePoint Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 9.013 million compared to USD 4.122 million a year ago. Operating loss was USD 10.979 million compared to USD 11.152 million a year ago. Net loss was USD 10.010 million compared to USD 12.950 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 1.04 a year ago. For the half year, total revenue was USD 16.336 million compared to USD 11.611 million a year ago. Operating loss was USD 21.914 million compared to USD 22.596 million a year ago. Net loss was USD 22.290 million compared to USD 26.124 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 2.17 a year ago.

Latest news about EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	Apr. 02	CI
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 07	MT
Transcript : EyePoint Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	Mar. 07	MT
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	Mar. 07	MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	Mar. 04	MT
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	Mar. 04	CI
Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	Feb. 15	MT
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	Feb. 03	CI
Certain Warrants of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Restricted Stock Units of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Options of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Common Stock of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing	Jan. 30	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing	Jan. 29	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing	Jan. 26	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing	Jan. 26	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing	Jan. 24	MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	Jan. 22	MT
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	Jan. 17	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing	Jan. 10	MT

Chart EyePoint Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Companyâs other products include YUTIQ, and DEXYCU.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for EyePoint Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.16 USD

Average target price

43.89 USD

Spread / Average Target

+171.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EYEPOINT PHARMACEUTICALS, INC.	-30.07%	805M
NOVO NORDISK A/S	+25.07%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.42%	233B
NOVARTIS AG	+5.62%	201B
ROCHE HOLDING AG	-10.10%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals